MXCT · XBRL financial data

MaxCyte financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MXCT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	33,894	44,262	41,288	38,627	33,026
Revenue from contracts with customers	21,571	28,749	19,497	22,215	20,957
Cost of goods and services sold	3,647	5,098	4,742	7,100	6,222
Gross profit	30,247	39,163	36,546	31,527	26,804
Research and development	15,407	19,514	23,817	22,227	20,823
General and administrative	18,676	25,829	30,068	29,693	28,116
Total operating expenses	48,435	66,524	84,845	82,724	78,701
Operating income (loss)	(18,189)	(27,361)	(48,299)	(51,197)	(51,897)
Interest income	151	3,917	10,376	10,142	7,267
Interest expense	5	—	—	—	—
Other income (expense)	(894)	3,790	10,376	10,142	7,267
Income tax expense (benefit)	0	—	—	—	—
Net income (loss)	(19,082)	(23,571)	(37,923)	(41,055)	(44,630)
Earnings per share, basic USD per share	(0.21)	(0.23)	(0.37)	(0.39)	(0.42)
Earnings per share, diluted USD per share	(0.21)	(0.23)	(0.37)	(0.39)	(0.42)
Weighted average shares, basic thousands of shares	90,619	101,703	103,269	104,849	106,428
Weighted average shares, diluted thousands of shares	90,619	101,703	103,269	104,849	106,428

Fiscal years (MXCT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	47,782	11,065	46,506	27,884	20,065
Short-term investments	207,261	216,275	121,782	126,598	82,979
Accounts receivable	6,877	11,655	5,778	4,682	3,503
Inventory	5,205	8,581	12,229	8,914	7,547
Prepaid and other current assets	3,307	2,779	3,899	3,606	4,275
Total current assets	270,433	252,266	190,194	171,684	118,369
Property and equipment, net	7,681	23,725	23,513	19,707	17,531
Right-of-use asset	5,689	9,854	11,241	10,766	10,920
Total assets	284,120	286,653	268,274	239,470	202,507
Accounts payable	1,820	532	743	1,358	1,401
Total current liabilities	15,618	15,427	17,855	15,775	14,267
Lease liability, non-current	5,155	15,938	17,969	17,170	16,487
Total liabilities	21,223	32,686	36,107	33,219	31,017
Accumulated deficit	(114,305)	(137,875)	(175,798)	(216,853)	(261,483)
Total stockholders' equity	262,897	253,967	232,167	206,251	171,490
Total liabilities and equity	284,120	286,653	268,274	239,470	202,507
Common shares outstanding (cover page) thousands of shares	101,509	102,905	104,129	106,028	106,861

Fiscal years (MXCT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(19,082)	(23,571)	(37,923)	(41,055)	(44,630)
Stock-based compensation	7,959	11,752	13,979	13,083	9,213
Depreciation and amortization	1,424	2,698	4,171	4,315	4,340
Net cash from operating activities	(10,680)	(14,783)	(21,686)	(27,610)	(34,410)
Purchases of property and equipment	3,834	18,477	3,700	1,651	1,768
Net cash from investing activities	(195,013)	(24,823)	54,984	6,932	25,935
Proceeds from issuing common stock	51,809	2,900	—	—	—
Net cash from financing activities	234,720	2,889	2,143	2,056	656
Net change in cash	29,027	(36,718)	35,441	(18,622)	(7,819)

SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Maxcyte	15,042	7,271	(4,661)*	103.2M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
NRC Health	3,327	35,392	1,386*	22.1M	—	Q2 FY26 10-QJun 30, 2026
Absci	107,865	not reported	(27,564)*	171.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
OmniAb	22,883	3,993	10,575*	145.9M	—	Q3 FY26 10-QSep 30, 2026
Neogenomics	139,281	209,254	(8,885)*	129.4M	18.9 quarters	Q3 FY26 10-QSep 30, 2026
Inotiv	15,180	117,652	(1,070)*	34.9M	14.2 quarters	Q2 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.